文献速递临床试验与 GCP流行病学与生物统计

BOHEMIA:非洲基于单一大健康体内杀寄生虫药的疟疾干预——一项在两种非洲环境中研究伊维菌素群体给药降低疟疾传播安全性及有效性的III期整群随机开放标签临床试验

BOHEMIA: Broad One Health Endectocide-based Malaria Intervention in Africa-a phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in two African settings.
PubMed 文献 · Trials · 2023-02-21

BOHEMIA是一项在东部和南部非洲两种生态流行病学条件下开展的整群随机、平行臂、优效性III期试验,比较每月一次连续3个月的人群伊维菌素给药、人群加牲畜伊维菌素给药与阿苯达唑对照对当地疟疾传播的影响。主要结局为每个整群核心区5岁以下儿童队列的疟疾发病率,采用每月快速诊断试验前瞻性随访。该试验将是首个评估仅人群或人群加牛群伊维菌素群体给药对当地疟疾传播影响的大规模试验。

要点

  • 伊维菌素人群给药方案为400 mcg/kg每月一次连续3个月,牲畜为200 mcg/kg单剂每月一次连续3个月。
  • 对照方案为阿苯达唑400 mg每月一次连续3个月。
  • 主要结局为整群核心区5岁以下儿童队列经每月快速诊断试验随访的疟疾发病率。

核心结论

  • BOHEMIA将是首个评估仅人群或人群加牛群伊维菌素群体给药对当地疟疾传播影响的大规模试验。

研究设计与样本

  • 整群随机、平行臂、优效性III期临床试验,在东部和南部非洲两种生态流行病学条件不同的环境中开展。

主要发现

  • 试验设三组:人群干预组为符合条件人群(>15 kg、非妊娠、无禁忌症)每月一次伊维菌素400 mcg/kg连续3个月。
  • 人群加牲畜干预组在人群给药基础上,对区域牲畜每月一次注射伊维菌素200 mcg/kg单剂连续3个月。
  • 对照组为阿苯达唑400 mg每月一次连续3个月。
  • 主要结局为每个整群核心区5岁以下儿童队列的疟疾发病率,采用每月快速诊断试验前瞻性随访。

局限性

  • 实施方案的第二个现场已从坦桑尼亚改为肯尼亚。
  • 本摘要呈现的是莫桑比克特定方案,更新后的总方案和改编后的肯尼亚特定方案正在肯尼亚接受国家审批。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Residual malaria transmission is the result of adaptive mosquito behavior that allows malaria vectors to thrive and sustain transmission in the presence of good access to bed nets or insecticide residual spraying. These behaviors include crepuscular and outdoor feeding as well as intermittent feeding upon livestock. Ivermectin is a broadly used antiparasitic drug that kills mosquitoes feeding on a treated subject for a dose-dependent period. Mass drug administration with ivermectin has been proposed as a complementary strategy to reduce malaria transmission. METHODS: A cluster randomized, parallel arm, superiority trial conducted in two settings with distinct eco-epidemiological conditions in East and Southern Africa. There will be three groups: human intervention, consisting of a dose of ivermectin (400 mcg/kg) administered monthly for 3 months to all the eligible population in the cluster (>15 kg, non-pregnant and no medical contraindication); human and livestock intervention, consisting human treatment as above plus treatment of livestock in the area with a single dose of injectable ivermectin (200 mcg/kg) monthly for 3 months; and controls, consisting of a dose of albendazole (400 mg) monthly for 3 months. The main outcome measure will be malaria incidence in a cohort of children under five living in the core of each cluster followed prospectively with monthly RDTs DISCUSSION: The second site for the implementation of this protocol has changed from Tanzania to Kenya. This summary presents the Mozambique-specific protocol while the updated master protocol and the adapted Kenya-specific protocol undergo national approval in Kenya. BOHEMIA will be the first large-scale trial evaluating the impact of ivermectin-only mass drug administration to humans or humans and cattle on local malaria transmission TRIAL REGISTRATION: ClinicalTrials.gov NCT04966702 . Registered on July 19, 2021. Pan African Clinical Trials Registry PACTR202106695877303.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chaccour C, Casellas A, Hammann F, et al. BOHEMIA: Broad One Health Endectocide-based Malaria Intervention in Africa-a phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in two African settings. Trials. 2023. PMID: 36810194. doi:10.1186/s13063-023-07098-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。